- Home
- TLX vs PTGX Comparison
TLX vs PTGX Comparison
Compare TLX & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLX
- PTGX
- Stock Information
- Founded
- TLX 2015
- PTGX 2006
- Country
- TLX Australia
- PTGX United States
- Employees
- TLX N/A
- PTGX N/A
- Industry
- TLX Biotechnology: Pharmaceutical Preparations
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- TLX Health Care
- PTGX Health Care
- Exchange
- TLX Nasdaq
- PTGX Nasdaq
- Market Cap
- TLX 3.6B
- PTGX 4.0B
- IPO Year
- TLX N/A
- PTGX 2016
- Fundamental
- Price
- TLX $10.63
- PTGX $76.75
- Analyst Decision
- TLX Strong Buy
- PTGX Strong Buy
- Analyst Count
- TLX 4
- PTGX 9
- Target Price
- TLX $21.00
- PTGX $78.11
- AVG Volume (30 Days)
- TLX 109.9K
- PTGX 1.5M
- Earning Date
- TLX 01-01-0001
- PTGX 10-31-2025
- Dividend Yield
- TLX N/A
- PTGX N/A
- EPS Growth
- TLX N/A
- PTGX N/A
- EPS
- TLX 0.04
- PTGX 0.80
- Revenue
- TLX $664,225,558.00
- PTGX $209,180,000.00
- Revenue This Year
- TLX N/A
- PTGX N/A
- Revenue Next Year
- TLX N/A
- PTGX $142.86
- P/E Ratio
- TLX $333.76
- PTGX $95.33
- Revenue Growth
- TLX 55.35
- PTGX N/A
- 52 Week Low
- TLX $8.93
- PTGX $33.31
- 52 Week High
- TLX $30.36
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- TLX 52.01
- PTGX 59.19
- Support Level
- TLX $10.74
- PTGX $73.08
- Resistance Level
- TLX $11.00
- PTGX $79.00
- Average True Range (ATR)
- TLX 0.28
- PTGX 2.93
- MACD
- TLX 0.04
- PTGX -0.37
- Stochastic Oscillator
- TLX 63.77
- PTGX 27.14
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.